Dispelling Myths About Psychedelics: In Conversation With Guy Goodwin, MD

Psilocybin-focused treatment for treatment-resistant depression is presented through Guy Goodwin, MD and COMP360, a synthetic formulation of psilocybin developed by Compass Pathways. Goodwin connects phase 3 results to clinical meaning: COMP360 achieved a primary endpoint with statistically significant MADRS symptom reduction, with benefits that appeared quickly after administration and were discussed as durable through up to 26-week follow-up, supported by low placebo response. He also contrasts the reported “waking dream” quality and short intense psychedelic phase (then fading over several additional hours) with effects from conventional psychotherapy. A key myth to dispel is stigma and presumed poor tolerability. Goodwin highlights acceptance in trial settings, describing that most participants were psychedelic-naive, that adverse effects largely resolved within 24 hours, and that a high proportion returned for a second dosing session aided by structured preparation, on-the-day support, and follow-up care. He frames mainstream psychiatric integration as dependent on regulatory approval and scalable delivery through interventional psychiatry sites.